Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

CLAIMS

We claim:

1 (Currently amended). ~~Novel anhydrous amorphous forms of bis[(E) [4-(4-fluorophenyl) isopropyl [methyl(methylsulfonyl)amino]pyrimidin yl](3R,5S) 3,5-dihydroxyhept enoic acid]calcium salt (rosuvastatin calcium), bis[(E) 3,5-dihydroxy 7-[4' (4'' fluorophenyl) 2' cyclopropyl quinolin 3' hept 6 enoic acid] calcium salt (pitavastatin calcium) and form of (±)7 (3 (4 fluorophenyl) 1 (1 methylethyl) 1H indol 2 yl) 3,5 dihydroxy heptenoic acid monosodium salt (fluvastatin sodium).~~ Anhydrous amorphous fluvastatin sodium, wherein it is free of water and its X-ray powder diffraction pattern lacking any discernible peaks and substantially in accordance with Figure 3.

2-7 (Cancelled)

8 (Currently amended). A process for [[the]] preparation of anhydrous amorphous ~~forms of bis[(E) [4-(4-fluorophenyl) isopropyl [methyl(methylsulfonyl)amino]pyrimidin yl](3R,5S) 3,5-dihydroxyhept enoic acid]calcium salts (rosuvastatin calcium), bis[(E) 3,5-dihydroxy 7 [4' (4'' fluorophenyl) 2' cyclopropyl quinolin 3' hept 6 enoic acid] calcium salt (pitavastatin calcium) and (±)7 (3 (4 fluorophenyl) 1 (1 methylethyl) 1H indol 2 yl) 3,5 dihydroxy heptenoic acid monosodium salt (fluvastatin sodium)~~ fluvastatin sodium of claim 1, comprising steps of:

(a) Dissolving crude or pure hydrate amorphous or crystalline form or their mixtures of ~~the Agents~~ fluvastatin sodium in a non-hydroxylic solvent;

(b) Adding a non-polar hydrocarbon anti-solvent or adding the dissolved ~~the Agents~~ fluvastatin sodium to the non-polar anti-solvent to precipitate out product;

and (c) removing the solvent by filtration to afford anhydrous amorphous ~~forms of rosuvastatin calcium, pitavastatin calcium and~~ fluvastatin sodium.

9-12 (Cancelled)

13 (Original). The process according to claim 8, wherein the non-hydroxylic solvent is tetrahydrofuran and anti-solvent is chosen from a group of non-polar hydrocarbon solvents comprising n-hexane, cyclohexane or n-heptane.

14 (Original). The process according to claim 8, wherein the non-hydroxylic solvent is tetrahydrofuran and anti-solvent is n-hexane.

15 (Original). The process according to claim 8, wherein the non-hydroxylic solvent is tetrahydrofuran and anti-solvent is cylcohexane.

16 (Original). The process according to claim 8, wherein the non-hydroxylic solvent is tetrahydrofuran and anti-solvent is n-heptane.

17 (Currently amended). The process according to any of claims ~~8-16~~ 8, 11 and 13-16, which comprises cooling the solution and isolating the precipitated anhydrous amorphous form by filtration or centrifuging.

18 (Currently amended). A process for the preparation of anhydrous amorphous ~~forms of rosuvastatin calcium, pitavastatin calcium and~~ fluvastatin sodium of claim 1 by dissolving crude or pure hydrate amorphous or crystalline forms or their mixtures of ~~the Agents~~ fluvastatin sodium in acetonitrile or in straight or branched alkanol containing 1-4 carbon atoms or a mixture of such alkanols under heating and isolating the anhydrous amorphous ~~form of the Agents~~ fluvastatin sodium precipitated after cooling.

19-22 (Cancelled)

23 (Original). The process according to claim 18, alkanol solvent is selected from methanol, ethanol, isopropanol, butanol or their mixtures.

24 (Original). The process according to claim 18, alkanol solvent is preferably selected from ethanol and isopropanol.

25 (Original). The process according to claim 18, which comprises using acetonitrile or a mixture of acetonitrile and one or more alkanols.

26 (Currently amended). The process according to claim 18, which comprises dissolving ~~rosuvastatin calcium or pitavastatin calcium or~~ fluvastatin sodium in alkanols or acetonitrile at the boiling point of the solvent.

27 (Currently amended). The process according to any of claims ~~18-26~~ 18 and 23-26, which comprises cooling the solution and isolating the precipitated anhydrous amorphous ~~form~~ fluvastatin sodium by filtration or centrifuging.

28 (Currently amended). A pharmaceutical composition comprising an anhydrous amorphous ~~form of rosuvastatin calcium, piatavstatin calcium or~~ anhydrous amorphous fluvatsatin sodium of claim 1 and pharmaceutically acceptable carrier, diluent, excipient, additive, filler, lubricant, solvent binder or stabilizer.

29-31 (Cancelled)

32 (Original). A pharmaceutical composition according to claim 28, in the form of a tablet, troche, powder, syrup, patch, liposome, injection, dispersion, suspension, solutions, capsule, cream, ointment or aerosol.

33 (Cancelled)